Kallikrein Excretion and Epigenetics in Acute Kidney Injury
Author Information
Author(s): Kang Sun Woo, Shih Pei-an Betty, Mathew Roy O, Mahata Manjula, Biswas Nilima, Rao Fangwen, Yan Liying, Bouchard Josee, Malhotra Rakesh, Tolwani Ashita, Khandrika Srikrishna, Mehta Ravindra L, O'Connor Daniel T
Primary Institution: University of California at San Diego
Hypothesis
Urinary kallikrein levels would be associated with the severity of acute kidney injury and with epigenetic changes in the KLK1 promoter.
Conclusion
Increased KLK1 excretion in AKI patients is likely due to higher adrenergic tone during blood pressure depression.
Supporting Evidence
- Patients with established AKI displayed substantially elevated urine KLK1 excretion, ~11-fold higher than healthy controls.
- Lower systolic blood pressure and higher heart rate were observed in established AKI patients compared to healthy controls.
- Promoter KLK1 CpG methylation was higher in blood DNA from AKI patients than in healthy controls.
Takeaway
This study found that patients with kidney injury had higher levels of a protein called kallikrein in their urine, which might help doctors understand how severe the injury is and how well the kidneys are recovering.
Methodology
Urine and blood samples were collected from patients with acute kidney injury and healthy controls to measure KLK1 excretion and analyze DNA methylation.
Potential Biases
Potential biases may arise from the observational nature of the study and the specific patient population selected.
Limitations
The study did not evaluate other epigenetic mechanisms such as histone modifications and was limited by the number of subjects.
Participant Demographics
The study included 20 patients with established AKI and 38 healthy controls, with a mix of ethnicities.
Statistical Information
P-Value
2.09E-05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website